Any new drug prescribed by a hospital for the same purposes may be approved and can be manufactured in limited quantity. Credit: Pexels from Pixabay.

The Indian Health Ministry has issued a draft notification for ‘compassionate use’ of any unapproved drug that is in the Phase III clinical trial across the globe.

The draft New Drugs and Clinical Trials (Amendment) Rules seek to facilitate the availability of experimental drugs for severely ill Covid-19 patients.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

A gazette notification of the draft rules was published in this regard.

According to the notification, a hospital or medical institution may import new drugs for ‘compassionate use for treatment of patients suffering from life threatening disease or disease causing serious permanent disability or disease requiring therapy for unmet medical need,’ PTI reported.

Additionally, any new drug prescribed by a hospital for the same purposes may be approved and can be manufactured in limited quantity. This is subject to provisions of the rules.

These new rules have been inserted under section 96, which deals with filing an application and issues the license to the importer or manufacturer. The licence will remain valid for one year for manufacturing and importing, from the date it has been issued.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In the case where an importer or manufacturer who gets the license does not comply with any provision of the act and these rules, their license can be suspended or cancelled by the Central Licencing Authority.

The new draft rules will be applicable for a period of 15 days. During this time, people will be able to send their objections and suggestions which will be considered by the central government.

Later on, the final amended rules will be published in the gazette of India.